Sanofi-Synthelabo sells Arixtra and Fraxiparine to GSK for 453M euros
GlaxoSmithKline said on April 13 that it has signed an agreement to acquire, on a worldwide basis, Sanofi-Synthelabo's injectable antithrombotic agents Fraxiparine (nadroparine calcium) and Arixtra (fondaparinux sodium), as well as related assets including a manufacturing plant located in Notre-Dame de Bondeville, France.
The cost of the purchase is 453 million euros ($546.8 million), which GSK says will be paid in cash, noting that it will also undertake responsibility for ongoing Arixtra clinical trials.
Fraxiparine, a low-molecular weight heparin product, achieved sales of 319 million euros last year, while turnover for Arixtra, a synthetic factor Xa inhibitor, reached 24 million euros.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze